Published February 2009 | Version v1
Journal article

A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours

  • 1. Radiopharmacy Directory, Nuclear and Energetic Research Institute (IPEN), Av. Lineu Prestes, 2242, Cidade Universitaria, Butanta, CEP 05508-000, Sao Paulo (Brazil)

Description

This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to 177Lu-DOTATATE and with lower abdominal uptake than 131I-TATE. In addition, 131I-DOTATATE showed significative tumour uptake, despite not so persistent after 24 h. 131I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy

Availability note (English)

Available from http://dx.doi.org/10.1016/j.apradiso.2008.09.009

Additional details

Identifiers

DOI
10.1016/j.apradiso.2008.09.009;
PII
S0969-8043(08)00447-8;

Publishing Information

Journal Title
Applied Radiation and Isotopes
Journal Volume
67
Journal Issue
2
Journal Page Range
p. 227-233
ISSN
0969-8043
CODEN
ARISEF

Optional Information

Copyright
Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.